Browsing by Author "Kalra, P."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Persisting Menace of Pre Labour Rupture of Membranes Persisting Dilemmas.
    (2015-05) Chhabra, S.; Kalra, P.; Shrivastava, P.
    Objective : Prelabour rupture of membranes (PLROM) is common obstetric problem ,one of most common clinical events where normal pregnancy can turn into high risk situation for mother as well as fetus. Present study was to know incidence of term, preterm PLROM, association with parity ,body mass index, anaemia, cervical / vaginal colonization,cervical score, amniotic fluid index. Material and Methods : Study included 550 women of 18-35 years of age, 28-42 weeks of gestation who had presented with watery vaginal discharge in whom membrane rupture was confirmed. Results : Incidence of PLROM was 6.28% of births, 4.62% term births, 1.65% preterm births. Mean age of women was 24 years, mean BMI was 21.9. Ninety seven percent of women with PLROM were anaemic 18% of women had growth of microbes in cervical vaginal swabs.Forty eight percent women had cervical score less than zero, four percent had severe oligoamnios. Conclusion : Study revealed higher incidence of term,preterm PLROM in patients with anaemia, genital infection.By identifying, modifying risk factors we can help reduce maternal, fetal morbidity ,mortality associated with term, preterm PLROM
  • No Thumbnail Available
    Item
    Role of vildagliptin and its combination in type 2 diabetes mellitus management: a knowledge, attitude, and practice survey among Indian healthcare professionals
    (Medip Academy, 2024-08) Kalra, P.; Dharmalingam, M.; Kubba, S.; Bhojwani, H.; Jain, S.
    Background: Type 2 diabetes mellitus (T2DM) is a prevalent condition, with a significant burden in India, affecting approximately 74.2 million individuals. Vildagliptin, a selective dipeptidyl peptidase 4 (DPP-4) inhibitor, is approved globally for monotherapy and combination therapy. Recently, it became available as a generic product, which increased its accessibility to patients. This study aimed to assess the knowledge, attitude, and practice (KAP) regarding vildagliptin and its combination in T2DM management. Methods: A pan-India cross-sectional KAP survey was conducted from February 2022 to March 2023. The survey utilized a specially designed questionnaire focusing on various aspects of vildagliptin treatment. A total of 1,440 healthcare professionals (HCPs) with recognized qualifications and experience in diabetes management participated. Descriptive statistics were employed for data analysis. Results: HCPs reported initiating Vildagliptin monotherapy at an HbA1c 6.5-7.5%, while combination therapy with vildagliptin and metformin at HbA1c 7-8%. Vildagliptin was primarily preferred as an add-on to metformin. Inadequate HbA1c control with existing therapy emerged as the primary trigger for switching to vildagliptin and metformin combination. Treatment-na飗e T2DM patients with HbA1c 1.5% above target and those uncontrolled on metformin monotherapy or dual therapy were reported to benefit most from combination therapy. Combination therapy was reported to result in a glycemic reduction of 1.0-1.5%. HCPs perceived vildagliptin better than other DPP4 inhibitors due to its efficacy in reducing HbA1c and a lower risk of hypoglycemia. Conclusions: The KAP survey highlights the value Indian HCPs place on the effectiveness and tolerability of vildagliptin and their attitudes and practices in its use, highlighting its clinical utility in routine practice.